MAPK7 Antibody

What is MAPK7 and why is it important in cellular signaling?

MAPK7 (Mitogen-Activated Protein Kinase 7), also known as ERK5 (Extracellular Signal-Regulated Kinase 5), is a member of the MAP kinase family involved in various cellular processes including proliferation, differentiation, transcription regulation, and development. It functions within a canonical three-tiered MAPK signaling cascade comprising MEK5, MEKK2/3, and ERK5 itself . MAPK7 is specifically activated by MAP2K5/MEK5 and is involved in downstream signaling processes of various receptor molecules including receptor type kinases and G protein-coupled receptors . Upon activation by extracellular signals, MAPK7 translocates to the cell nucleus where it regulates gene expression by phosphorylating and activating different transcription factors .

MAPK7 is expressed in many adult tissues, most abundantly in heart, placenta, lung, kidney, and skeletal muscle, but is notably not detectable in liver . The importance of MAPK7 is underscored by studies showing that gene deletion in mice results in defective blood vessel and cardiac development leading to embryonic lethality .

How do I select the appropriate MAPK7 antibody for my research?

Selection of an appropriate MAPK7 antibody depends on several key factors:

Before selecting, check reported molecular weight detection patterns, as MAPK7 shows variable observed molecular weights (ranging from 50 kDa to 89 kDa) depending on post-translational modifications and isoform detection .

What are the recommended storage conditions for MAPK7 antibodies?

Most MAPK7 antibodies require specific storage conditions to maintain integrity and activity:

• Store at -20°C for long-term storage

• Aliquot to avoid repeated freeze-thaw cycles which can degrade antibody quality

• Some formulations are stable for up to one year after shipment when stored correctly

• After reconstitution, antibodies can typically be stored for up to one month at 4°C

• Most antibodies are supplied in buffer containing preservatives such as sodium azide and stabilizers like glycerol (typically 40-50%)

For lyophilized antibodies, reconstitution should be performed with sterile DI water or as specified in the product documentation .

What are the optimal dilutions for MAPK7 antibodies in different applications?

Optimal antibody dilutions vary by application, antibody source, and experimental conditions:

It is strongly recommended to perform a dilution series to determine the optimal concentration for your specific experimental conditions and sample types . Many antibodies show tissue-specific or cell line-specific optimal dilutions that differ from the manufacturer's general recommendations.

How should I validate MAPK7 antibody specificity in my experimental system?

Thorough validation of MAPK7 antibody specificity is critical for generating reliable data:

• Positive and negative controls:

  • Use cell lines with known MAPK7 expression levels (e.g., SKOV-3, HEK-293 cells show positive WB detection)

  • Include tissue samples with known expression (heart, placenta show high expression; liver shows minimal expression)

• Knockdown/knockout validation:

  • Perform siRNA knockdown experiments as demonstrated in studies with KYSE30 and SNU449 cell lines

  • Compare antibody signal between wild-type and MAPK7-silenced samples

• Molecular weight verification:

  • MAPK7 has a calculated molecular weight of 89 kDa but is often observed at 70-80 kDa

  • Phosphorylated MAPK7 shows a gel shift in molecular weight

• Cross-reactivity testing:

  • Test on multiple species if performing comparative studies

  • Verify isoform specificity if targeting specific MAPK7 variants

• Peptide competition assay:

  • Pre-incubate antibody with the immunogen peptide to confirm signal specificity

What are the most effective antigen retrieval methods for MAPK7 immunohistochemistry?

Effective antigen retrieval is crucial for optimal MAPK7 detection in fixed tissues:

• For paraffin-embedded tissues, TE buffer (pH 9.0) is often recommended as the primary antigen retrieval method

• Alternative approach: citrate buffer (pH 6.0) can be used if TE buffer yields suboptimal results

• For formalin-fixed frozen sections, dilutions of 1:100-1:500 are typically effective

• Antigen retrieval conditions should be optimized based on tissue type and fixation duration

• Some protocols recommend pressure cooker-based antigen retrieval for improved epitope accessibility

When performing IHC with MAPK7 antibodies, validation with positive control tissues is essential, with human stomach tissue being confirmed as an effective positive control for some antibodies .

How can MAPK7 antibodies be used to study cancer progression and metastasis?

MAPK7 antibodies have been instrumental in elucidating the role of this kinase in cancer:

• Detection of gene amplification and protein overexpression:

  • MAPK7 gene amplification has been identified in 4% of non-small cell lung cancers (NSCLC) (enriched to 6% in squamous cell carcinoma) and 2% of squamous esophageal cancers (sqEC)

  • IHC analysis revealed good correlation between MAPK7 gene amplification and protein expression

• Investigation of epithelial-to-mesenchymal transition (EMT):

  • MAPK7 knockdown increases E-cadherin (CDH1) expression and inhibits cell migration

  • MAPK7 regulates Snai2, a master regulator of EMT

  • Using antibodies against phosphorylated MEF2A and MEF2D can serve as downstream pharmacodynamic biomarkers of MAPK7 inhibition

• Metastasis studies:

  • MAPK7 suppression reduces the generation of circulating tumor cells (CTCs) and lung metastases in orthotopic mouse models

  • MAPK7 antibodies can be used to monitor its expression in primary tumors versus metastatic lesions

• Therapy response monitoring:

  • MAPK7 inhibition by compounds like XMD8-92 can be monitored using phospho-specific antibodies

  • Protein microarray analysis with MAPK7 antibodies can identify novel downstream targets affected by inhibitors

This application is particularly valuable as MAPK7 has been established as a proliferative oncogenic driver in various tumor types through siRNA knockdown validation studies .

What are the key considerations when designing phospho-MAPK7 detection assays?

Detecting phosphorylated MAPK7 presents unique challenges that require specific considerations:

• Phospho-specific antibodies:

  • Select antibodies specifically targeting phosphorylated residues (typically Thr218/Tyr220)

  • Verify antibody recognition of phosphorylated versus non-phosphorylated forms

• Activation induction:

  • MAPK7 phosphorylation can be induced by co-expression with constitutively active MEK5 (MEK5CA)

  • Gel shift assays can confirm activation status as phosphorylated MAPK7 shows higher molecular weight

• Assay development:

  • Sandwich ELISA using appropriate antibody pairs offers quantitative phospho-MAPK7 detection

  • Include positive controls (MEK5CA co-expression) and negative controls (kinase inhibitor treatment)

• Sample preparation:

  • Use phosphatase inhibitors during cell/tissue lysis to preserve phosphorylation status

  • Process samples quickly and maintain cold temperatures throughout

• Downstream monitoring:

  • Phosphorylation of MEF2A (S408), MEF2D (S444), and other targets can serve as surrogate markers of MAPK7 activity

  • Reverse-phase protein array (RPPA) can identify additional phosphorylation events

A high-throughput ELISA-based phospho-MAPK7 assay has been successfully developed using commercially available antibody pairs, demonstrating good signal-to-noise ratio for detecting MAPK7 activation states .

How do researchers investigate the role of MAPK7 in tissue-specific developmental processes?

Investigation of MAPK7's role in development requires specific experimental approaches:

• Tissue expression profiling:

  • Analyze MAPK7 expression across developmental stages using tissue microarrays

  • Compare with known developmental markers to establish temporal relationships

• Conditional knockout/knockdown models:

  • Generate tissue-specific MAPK7 knockdown models to avoid embryonic lethality

  • Use inducible systems to control timing of MAPK7 deletion

• Vascular and cardiac development:

  • MAPK7 is critical for endothelial function and blood vessel integrity

  • Co-staining with endothelial markers helps define MAPK7's role in vascular formation

• Cancer stem cells:

  • Investigate MAPK7's role in maintaining cancer stem cell properties

  • Correlate expression with stemness markers in tissue samples

• Cellular differentiation:

  • Monitor MAPK7 expression and activity during differentiation processes

  • Examine relationship with lineage-specific transcription factors

These approaches have revealed MAPK7's important functions in vascular integrity and cardiac development, with gene deletion in mice resulting in embryonic lethality due to defects in these systems .

How can discrepancies in MAPK7 antibody detection patterns be explained and resolved?

Researchers often encounter variability in MAPK7 detection patterns which can be explained by several factors:

• Molecular weight variations:

  • The calculated molecular weight of MAPK7 is 89 kDa, but observed weights range from 50-88 kDa

  • Different isoforms from alternative splicing contribute to size variations (four transcript variants reported)

  • Post-translational modifications, particularly phosphorylation, cause gel shifts

• Expression level discrepancies:

  • MAPK7 expression varies significantly between tissues and cell lines

  • Genomic amplification correlates with protein overexpression in some, but not all cases (e.g., in NSCLC samples)

  • Some tumors show IHC3+ protein staining without gene amplification

• Resolution strategies:

  • Use multiple antibodies targeting different epitopes to confirm results

  • Include appropriate positive controls (e.g., KYSE30 and SNU449 cell lines)

  • Perform parallel detection methods (WB, IHC, qPCR) to correlate results

  • Consider isoform-specific detection when analyzing results

This approach has helped researchers resolve apparent contradictions, such as the observation that some clinical NSCLC samples show high MAPK7 protein expression without corresponding gene amplification .

What are the most common technical issues when using MAPK7 antibodies and how can they be overcome?

Several technical challenges commonly arise when working with MAPK7 antibodies:

Additional recommendations:

• For sandwich ELISA development, careful selection of capture and detection antibody pairs is crucial to avoid epitope interference

• When analyzing phosphorylation status, rapid sample processing with phosphatase inhibitors is essential

• For reproducible results in IHC, consistent section thickness and standardized staining protocols are critical

How can researchers accurately quantify MAPK7 expression levels across different experimental systems?

Accurate quantification of MAPK7 across systems requires standardized approaches:

• Normalization strategies:

  • For Western blot: normalize to housekeeping proteins (β-actin, GAPDH) or total protein stains

  • For IHC/ICC: use scoring systems (e.g., IHC0 to IHC3+) as demonstrated in NSCLC tissue analysis

  • For qPCR: select stable reference genes appropriate for the specific tissue/condition

• Absolute quantification:

  • ELISA with recombinant protein standards for absolute protein quantification

  • Digital PCR for absolute transcript copy number

• Multi-platform validation:

  • Correlate protein levels (Western blot/IHC) with mRNA expression (qPCR)

  • Compare FISH analysis for gene copy number with protein expression levels

• Reproducibility considerations:

  • Include common control samples across experiments

  • Use automated image analysis software for consistent IHC/ICC quantification

  • Document lot numbers of antibodies as performance may vary between lots

In clinical samples, researchers have established effective systems correlating FISH analysis of MAPK7 gene amplification with IHC protein expression scoring (IHC0 to IHC3+), finding that all MAPK7-amplified cases demonstrated IHC3+ staining .

How are MAPK7 antibodies being used to develop new therapeutic approaches for cancer?

MAPK7 antibodies play a critical role in developing and evaluating anti-cancer therapeutic strategies:

• Target validation:

  • siRNA knockdown studies using MAPK7 antibodies for detection confirm its role as an oncogenic driver in amplified cell lines

  • IHC screening of patient samples identifies potential responders to MAPK7-targeted therapies

• Pharmacodynamic biomarker development:

  • Phospho-specific antibodies monitor inhibitor efficacy (e.g., compounds XMD8-92, Gray#18, Gray#21)

  • Downstream targets identified by protein microarray (pCDC25C, pCDKN1, pMEF2A, pMEF2D) serve as surrogate markers of MAPK7 inhibition

• Combination therapy assessment:

  • MAPK7 antibodies help evaluate synergistic effects with other targeted therapies

  • Monitor pathway reactivation or compensatory mechanisms during treatment

• Resistance mechanism studies:

  • Compare MAPK7 expression/phosphorylation in sensitive versus resistant tumors

  • Identify changes in downstream signaling using antibody-based approaches

These approaches have facilitated development of MAPK7 inhibitors with measured cellular IC50 values, advancing therapeutic targeting of this pathway in cancers with MAPK7 dysregulation .

What are the latest techniques for multiplex detection of MAPK7 and related signaling proteins?

Cutting-edge approaches for multiplex analysis of MAPK7 signaling include:

• Reverse-phase protein arrays (RPPA):

  • Successfully used to identify downstream targets of MAPK7 inhibition in KYSE30 cells

  • Enables simultaneous analysis of numerous phosphorylation events

  • Identified pCDC25C, pCDKN1, pMEF2A and pMEF2D as significant targets with 55-60% signal reduction upon MAPK7 inhibition

• Multiplexed immunofluorescence:

  • Co-staining for MAPK7 with downstream targets or pathway components

  • Spatial relationship analysis within tissue microenvironments

  • Sub-cellular localization patterns before and after pathway activation

• RNA-in situ hybridization with protein detection:

  • Dual-colorimetric RNA-ISH combined with protein detection

  • Used to quantify epithelial and mesenchymal transcripts in relation to MAPK7 expression

  • Enabled scoring of E+ cells in primary tumors and metastatic lesions

• Mass cytometry (CyTOF):

  • Antibody-based detection of multiple pathway components with metal isotope tags

  • Single-cell resolution of MAPK pathway activation states

  • Correlation of MAPK7 with numerous other signaling nodes

These techniques have revealed complex relationships between MAPK7 signaling and cellular phenotypes, particularly in cancer progression and epithelial-to-mesenchymal transition .

How do researchers address the challenge of comparing results from different MAPK7 antibody sources in meta-analyses?

Researchers conducting meta-analyses of MAPK7 studies must address variability between antibody sources:

• Standardization approaches:

  • Document antibody catalog numbers, clones, and epitopes

  • Record specific application parameters (dilution, incubation time, detection method)

  • Note observed molecular weights and banding patterns for each antibody

• Cross-validation strategies:

  • Test multiple antibodies on identical samples

  • Correlate with orthogonal detection methods (mRNA expression, reporter systems)

  • Use recombinant MAPK7 as a universal standard

• Statistical considerations:

  • Account for antibody-specific variation in statistical models

  • Develop normalization algorithms based on common control samples

  • Use ratio-based measurements rather than absolute values when comparing across antibodies

• Reporting standards:

  • Follow ARRIVE guidelines for animal studies and antibody reporting

  • Document detailed methodologies to enable reproduction

  • Include all relevant controls and validation data

These practices are particularly important given the diversity of available MAPK7 antibodies, with over 670 antibodies from 40 providers currently documented , and their variable performance across different experimental systems.